Your patient KG has a history of atherothrombosis and a prior MI. If she is treated with ticagrelor + ASA instead of ASA alone, for which adverse event is she at greatest risk?
- TIMI bleeding
Correct Answer: A
The PEGASUS trial examined if adding ticagrelor to standard antiplatelet therapy (low-dose aspirin) would reduce the incidence of major adverse cardiovascular events during long-term follow-up in patients with a history of MI. The researchers found that adding ticagrelor to low-dose ASA in stable patients with a history of MI did reduce the risk of CV death, MI and/or stroke. Adding ticagrelor increased the risk of TIMI major and minor bleeding, but not fatal bleeding or ICH. They examined both 60mg BID and 90mg BID doses; while both had similar efficacy, adverse events were more frequent in the 90mg group.
Bonaca MP, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015 Mar 14. [Epub ahead of print]
Join your colleagues at Bringing Science to Clinical Practice: Best of ACC 2015 in one of two locations — May 29 – 30 in Miami or June 12 – 13 in Chicago — to examine ACC.15 highlights from new guidelines, late-breaking clinical trials, state-of-the-art sessions and more!
Attend the pre-conference session as faculty compare and contrast the newly emerging PCSK9 inhibitors.
Don't miss this groundbreaking and intimate educational opportunity!